Wikisage, the free encyclopedia of the second generation, is digital heritage
Valproate XR: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (value) |
||
| Line 1: | Line 1: | ||
improved compliance was observed with valproic acid and divalproex sodium<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778358/pdf/epc0009-0153.pdf Extended-Release Formulations of antiepileptic drug: Rationale and comparative value</ref> | improved compliance was observed with valproic acid and divalproex sodium<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778358/pdf/epc0009-0153.pdf Extended-Release Formulations of antiepileptic drug: Rationale and comparative value</ref> | ||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771963/ Immediate switching from a chrono to an extended-release formulation of divalproex sodium: A two-part study in patients with controlled epilepsy] | The patients had significantly less lateral effects (e.g. headaches, tremor of hands, and gastric upset a aggression were less) | ||
<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771963/ Immediate switching from a chrono to an extended-release formulation of divalproex sodium: A two-part study in patients with controlled epilepsy]</ref> | |||
<references/> | <references/> | ||
Revision as of 04:00, 1 July 2016
improved compliance was observed with valproic acid and divalproex sodium[1] The patients had significantly less lateral effects (e.g. headaches, tremor of hands, and gastric upset a aggression were less) [2]
- ↑ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778358/pdf/epc0009-0153.pdf Extended-Release Formulations of antiepileptic drug: Rationale and comparative value
- ↑ Immediate switching from a chrono to an extended-release formulation of divalproex sodium: A two-part study in patients with controlled epilepsy